This may be a complex result of gemcitabine’s cytotoxicity, and the anti-CTHRC1 antibody’s inhibition of tumor ECM production and facilitation of gemcitabine sensitivity through the inhibition of growth factors, such as HGF. The gene discussed is CTHRC1; the disease is neoplasm.